The QualityStocks Daily Friday, December 10th, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(SGMA) $14.9400 +84.67%

QualityStocks(VBIX) $0.1160 +45.00%

SmallCapRelations(SPYR) $0.0584 +32.61%

The QualityStocks Daily Stock List

Qutoutiao (QTT)

MarketClub Analysis, MarketBeat, StreetInsider, TradersPro, Schaeffer's, Wealth Insider Alert, Trading Concepts, Trades Of The Day, QualityStocks, InvestorsUnderground, INO Market Report and Daily Trade Alert reported earlier on Qutoutiao (QTT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Qutoutiao Inc. (NASDAQ: QTT) is a news recommendation app which operates as a news and video content platform in China. The firm, whose name means fun headlines, allows the distribution, sharing and consumption of light reading with entertainment as its primary content.

Qutoutiao Inc. was established in June 2016 by Lei Li and Eric Siliang Tan and is based in Shanghai, the People’s Republic of China. Before changing its name in July 2018, the firm was known as Qtech Ltd.

Qutoutiao Inc.’s mainly operates through these mobile platforms: Quduopai and Qutoutiao. The latter focuses on stories, humor and other light entertainment content that inspires and delights while the former is a mobile application which permits users to view, upload and create video content using mobile phones and offers customized real-time feeds to its users based on their social relationships, behavior and profile.

In addition to providing short videos and articles that are optimized through a machine learning algorithm, Qutoutiao Inc. launched Midu Novels which is a mobile literature application that offers its consumers free literature that’s supported by advertising and alternative version of the app called Midu Lite.

Qutoutiao Inc. is working towards diversifying their monetization strategies and product portfolio, which will not only boost their growth but also their earnings.

Qutoutiao (QTT), closed Friday's trading session at $3.7, up 791.5663%, on 688,920 volume with 3,632 trades. The average volume for the last 3 months is 688,670 and the stock's 52-week low/high is $3.599/$56.40.

Viewbix, Inc. (VBIX)

Small Cap Firm, QualityStocks, StockHideout, StockWireNews, StockOnion, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, Penny Pick Finders, OTCtipReporter, Leading Penny Stocks, HotOTC and Fierce Analyst reported earlier on Viewbix, Inc. (VBIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Viewbix, Inc. is a video analytics and technology company listed on the OTC Markets Group’s OTCQB. Viewbix helps companies understand what messages are resonating with their video viewers and how to take advantage of that data to enrich and empower a more effective video experience. The Company offers self- and fully managed solutions that companies can leverage across numerous distribution channels. The Company’s state-of-the-art video analytics and engagement platforms are used by prominent brands, agencies, as well as networks worldwide. Viewbix has its corporate headquarters in Herzliya, Israel.

The Company’s patented video marketing platform enables organizations the ability to drive a meaningful ROI (Return on Investment) rapidly and easily from their on-demand and live videos. This is while providing extensive insights into viewer engagement.

The Viewbix creative studio and analytics suite transforms standard video assets into interactive ones. This drives ROI in a matter of minutes. It does so while providing real time campaign optimization based on current and historical data.

Previously, Viewbix announced that it partnered with Doctorpedia, a health media network of condition-specific medical websites delivering credible and engaging video and written content powered by real doctors. Doctorpedia is working with Viewbix to speed up the patient journey and drive more extensive engagement by way of digital video.

Using Viewbix’s proprietary platform, Doctorpedia is able to optimize metrics such as time spent on their site and click-through rates. It helps Doctorpedia identify when viewers are most likely to engage with their videos and place desirable calls-to-action to sponsors and partners.

In addition, the Viewbix Studio enables Doctorpedia to improve related content including other videos and articles via the actionable intelligence the data provides. Partnering with Viewbix permits Doctorpedia to effectively place the most impactful calls-to-action in videos, and take advantage of resulting data to provide the most relevant next steps and ensure the best possible outcomes for patients and services.

Viewbix, Inc. (VBIX), closed Friday's trading session at $0.116, up 45%, on 4,283,830 volume with 617 trades. The average volume for the last 3 months is 4.284M and the stock's 52-week low/high is $0.014/$0.224.

Curative Biotechnology (CUBT)

We reported earlier on Curative Biotechnology (CUBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Curative Biotechnology Inc. (OTC: CUBT) is a development stage biopharmaceutical firm that is engaged in the identification, acquisition and development of new treatments for rare ailments using hemp-derived CBD (cannabidiol).

The firm has its headquarters in Boca Raton, Florida and was incorporated in 1995, on July 29th by Jon Pevzner. Prior to its name change, the firm was known as Amaize Beverage Corporation and does business as Connectyx. It operates in the healthcare sector, under the biotech and pharma sub-industry. The firm serves consumers across the globe.

The enterprise’s product segment is centered on manufacturing, marketing and selling plant-based CBD products to various market sectors. It has ongoing programs in a trio of therapeutic areas: degenerative eye disease, neuro-oncology and infectious diseases. The enterprise manufactures, markets and sells products via its consumer products business, under the Curative Biosciences Brand.

The company’s pipeline includes a new immune therapy indicated for the treatment of rabies known as IMT 504; and an antibody conjugate that targets CD56 positive brain tumors known as CURB906. Other products include medical consulting-billing, revenue cycle management, disease management, medical and product transcription, personal emergency response services, Medical Alert, electronic Personal Health Manager and MedFlash.

The firm recently filed its quarter one report for 2021, which highlights the progress the firm has made in assembling an experienced management team for their clinical development enterprise. This, coupled with the firm’s pipeline of promising treatments, is bound to bring in more investments into Curative Biotechnology Inc., which will in turn boost growth.

Curative Biotechnology (CUBT), closed Friday's trading session at $0.065, up 25%, on 1,471,225 volume with 109 trades. The average volume for the last 3 months is 1.471M and the stock's 52-week low/high is $0.0251/$0.2195.

CGrowth Capital (CGRA)

PennyStocks24, QualityStocks, Penny Stocks VIP, Penny Pick Insider, Daily Stock Motion, Jet-Life Penny Stocks, OTPicks, Penny Investor Network, Pumps and Dumps, PennyDoctor, InvestorPlace, Winston Small Cap, Penny Picks, Damn Good Penny Picks, OTCPicks, OTCMagic, OTC Magic, Wallstreetlivechat, Greenbackers, Penny Champions, Whisper from Wall Street, Center Stage Stocks, AllPennyStocks, AimHighProfits, InsideBulls, Otcstockexchange, TheMicrocapNews, Stock Twiter, Penny Dreamers, 007 Stock Chat, The Observer, Penny Stock Newsletter, StockRunway, Penny Trackers, Stockgoodies, PennyStockSpy, Pennystocktweeters.com, Promotion Stock Secrets and OtcWizard reported earlier on CGrowth Capital (CGRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CGrowth Capital Inc. (OTC: CGRA) is a holding firm for assets and businesses that is focused on exploration, mineral and mining activities and also commercial real estate in the U.S.

The firm has its headquarters in Silverdale, Washington and was incorporated in 1986, on October 30th. Prior to its name change in February 2010, the firm was known as Anchor Pacific Underwriters Inc.

The enterprise’s solutions and services have been designed to help land owners monetize undervalued assets by bringing commodities like gas and oil, silver, gold and dolomite to market. It builds value via the proving of reserves and generating revenues from its many projects. The enterprise is actively engaged in evaluating opportunities in the burgeoning legalized marijuana and hemp sectors.

The company is focused on the acquisition of land assets while also offering affiliates and partners with logistical, contract management, capital and management services necessary for operation execution. This is in addition to offering processing applications and support for land owners. It owns roughly 50 acres of industrial property in Chewelah, Washington; more than 1100 acres of oil leases in Louisiana and about 3400 acres of oil leases in the Powder River Basin. Its gas and oil division Powder River Resources Inc. is an independent gas and oil exploration firm.

The firm has plans to enter into a partnership initiative with Eyecity.com Inc. which will help finance and develop a marijuana retail and industrial epicenter. If successful, the venture will bring in additional revenue as well as encourage more investors to inject funds into the firms, which will in turn boost its growth.

CGrowth Capital (CGRA), closed Friday's trading session at $0.016, up 19.403%, on 16,839,474 volume with 490 trades. The average volume for the last 3 months is 16.839M and the stock's 52-week low/high is $0.0033/$0.0316.

Verus International, Inc. (VRUS)

Dynamic Wealth Report, The Street, QualityStocks, StreetInsider, OTCPicks, Cabot Wealth, ChartAdvisor, Greenbackers, Barchart, BestOtc, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, InvestmentHouse, MarketBeat, Wyatt Investment Research, PennyOmega, PennyToBuck, SmallCap Network, StockHotTips, StockMister, The Online Investor, Trading Markets, TradingMarkets and InvestorGuide reported earlier on Verus International, Inc. (VRUS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Verus International, Inc. operates a global food subsidiary (Verus Foods) that sells branded consumer products to customers around the world. The Company has developed premier food products sourced in the U.S. and exported them internationally. Verus works very closely with its local and international suppliers to deliver the finest food products at reasonable prices.

The Company lists on the OTC Markets Group’s OTCQB. Verus International has its corporate headquarters in Gaithersburg, Maryland. It was previously known as RealBiz Media Group, Inc. The Company changed its name to Verus International, Inc. in October of 2018.

Verus centers on the regional sensitivities and dietary requirements in the markets that it exports to. The Company’s dedication is to quality control and food safety. It closely monitors every step of the process meticulously. This is to ensure its strict food quality and production guidelines are met. This is from sourcing, production, packing, to shipping.

Verus International’s products include Condiments, Meat & Poultry, Ice Creams, Vegetables/French Fries, Commodities, and Candy. Commodities include Pulses & Legumes, Grains, as well as Rice. Verus Foods distributes and delivers its food products via an array of channels. This includes wholesale, van sales, retail and HORECA (Hotel/Restaurant/Café).

Recently, CRUS finalized a distribution and product development agreement (“Agreement”) with Texas-based Toro Imports (“Toro”), one of the largest CBD and related lifestyle products distributors in the industry. Under this Agreement, Toro will distribute Verus’ Pachyderm line of CBD products and will also work with Pachyderm to develop new products in emerging high-demand market segments. Toro will also carry Pachyderm CBD products in its own chain of retail stores.

The initial launch will cover approximately 1,000 locations, with a longer-term goal of reaching all 5,000 plus locations served by the Toro sales network. Initial distribution will begin in Texas, then expand to Florida, Georgia and New Jersey. The initial launch will concentrate on 25 to 30 of Pachyderm SKUs.

Verus International, Inc. (VRUS), closed Friday's trading session at $0.037, up 228.8889%, on 10,045,659 volume. The average volume for the last 3 months is 10.046M and the stock's 52-week low/high is $0.0101/$0.50.

International Isotopes (INIS)

QualityStocks, MarketBeat, SmallCapVoice and Orbit Stocks reported earlier on International Isotopes (INIS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

International Isotopes Inc. (OTCQB: INIS) is focused on the manufacture and sale of nuclear medicine reference standards, contract radiochemical and radiopharmaceutical manufacturing services and cobalt-60 products.

The firm has its headquarters in Idaho Falls, Idaho and was incorporated in 1995. It serves consumers around the globe, with a focus on the United States. The firm’s objective is to provide the highest quality products and best customer services in the marketplace today. Geographically, it generates most of its revenue from the United States.

The enterprise operates through the Fluorine products, Radiological services, Cobalt products, Nuclear Medicine standards and Radiochemical products. The Fluorine product segment is engaged in producing small scale qualification samples of high purity fluoride gas for different industrial applications. This is in addition to being involved in the development of lab processes needed to support fluorine extraction and uranium de-conversion facility. The radiological services segment is involved in a wide array of miscellaneous services which comprise of gemstone processing and field services like removal and source installation. The nuclear segment comprises of patient positioning, the manufacture of standards and sources linked to single photon emission computed tomography imaging and operational testing for measuring equipment for the nuclear pharmacy industry. On the other hand, the cobalt segment is focused on various cobalt refining processes while the radiochemical segment is involved in producing and distributing isotopically pure radio chemicals for different applications.

The company has entered into a licensing agreement with Memorial Sloan Kettering Cancer Center for an antibody test for detecting the virus that causes COVID-19. This move gives the company exclusive right to commercialize the invention which will have a positive effect on investments into the company as well as its revenues.

International Isotopes (INIS), closed Friday's trading session at $0.1, off by 2.439%, on 256,479 volume with 23 trades. The average volume for the last 3 months is 256,479 and the stock's 52-week low/high is $0.04/$0.34.

Bright Health Group (BHG)

MarketBeat, Trades Of The Day and Daily Trade Alert reported earlier on Bright Health Group (BHG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bright Health Group Inc. (NYSE: BHG) is an integrated care delivery firm that is focused on the delivery and financing of health insurance plans.

The firm has its headquarters in Minneapolis, Minnesota and was incorporated in 2015. Prior to its name change in February 2021, the firm was known as Bright Health Inc. It operates as part of the insurance carriers industry. The firm has seven firms in its corporate family and serves consumers in the United States.

The company aligns the best local resources in healthcare delivery with the financing of care, which helps lower costs, decrease systemic waste, optimize clinical outcomes and drive superior consumer experience. It generates revenue from income from investments as well as premiums, which include fee-for-service provider revenue received from payers and consumers, and value-based provider revenue.

The enterprise operates through the Bright Health Care and NeueHealth segments. Through the former segment, it provides commercial health plan products and Medicare products to roughly 620,000 consumers in 199 markets and fourteen states. The enterprise, through its latter segment, delivers high-quality in-person and virtual clinical care to about 75,000 patients via its 61 affiliated risk-bearing primary care clinics. In addition to this, it offers services through Care Partners, a network of hospitals, clinics and doctors.

The company has a strategic investment with Cigna Ventures, which brings deep healthcare expertise that complements the company’s mission of expanding access to affordable and quality healthcare. This move will also bring in more investors into the company as well as extend their consumer reach, which will be good for its growth.

Bright Health Group (BHG), closed Friday's trading session at $4.35, even for the day, on 5,967,202 volume with 21,330 trades. The average volume for the last 3 months is 5.888M and the stock's 52-week low/high is $3.07/$17.93.

Elevation Oncology (ELEV)

Actual Gains, PennyStockRumors.net, OTCPicks, Buzz Stocks, FeedBlitz, HEROSTOCKS, Liquid Pennies, MarketBeat, PennyTrader Publisher, WhisperFromWallStreet, QualityStocks, SmallCapStockPlays, Stock Brain, Stock Exploder, Stockhunter.us, VIP STOCK ALERTS and Otcstockexchange reported earlier on Elevation Oncology (ELEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elevation Oncology Inc. (NASDAQ: ELEV) is a clinical-stage biopharmaceutical firm that is engaged in the development of therapeutics for treating cancer in genomically-defined patient populations.

The firm has its headquarters in New York and was incorporated in 2019 by Shawn M. Leland. It serves consumers in the United States.

The company’s objective is to introduce new targeted therapies for patients with cancer as well as illuminate what the company is doing to create a future where every patient can receive care built around targeting their unique tumor drivers and understanding. This will be done by having every tumor’s unique genomic test result matched with a purpose-built precision medicine that will allow the use of individualized treatment plans for patients.

The enterprise’s formulations identify and target inhibition of tumor-specific drive alterations. Its product portfolio comprises of an anti-HER3 monoclonal antibody dubbed seribantumab, which is undergoing a phase 2 Crestone trial evaluating its effectiveness in treating advanced solid tumors that harbor neuregulin-1 fusions (NRG1 fusions).The NRG1 gene fusions are rare genomic alterations which combine NRG1 with other partner proteins to create a chimeric NRG1 fusion protein. These fusions have been identified in a variety of solid tumors, including cholangio carcinomas, neuroendocrine, colorectal, ovarian, breast, gallbladder, pancreatic, lung and sarcomas.

The firm is focused on making progress on its mission to bring purpose-built medicines to patients suffering from genomically defined cancers. The success of their formulations will not only address unmet needs in patients but also bring in more investments into the firm.

Elevation Oncology (ELEV), closed Friday's trading session at $5.45, up 6.8627%, on 51,465 volume with 575 trades. The average volume for the last 3 months is 51,465 and the stock's 52-week low/high is $4.25/$16.22.

iGen Networks Corp (IGEN)

QualityStocks, SmallCapVoice, RedChip, The Green Baron, StockGuru, Equities.com, equities Canada and MarketBeat reported earlier on iGen Networks Corp (IGEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

iGen Networks Corp (OTC: IGEN) (CNSX: IGN) is focused on the development and marketing of software services for the fleet management and automotive industry.

The firm has its headquarters in Lake Elsinore, California and was incorporated on 2006, on November 14th. Prior to its name change in June 2009, the firm was known as Sync2 Entertainment Corporation. It serves consumers in the United States.

The company works with privately held technology firms to help accelerate their growth. It works closely with these firms via sourcing of management expertise and expansion of distribution channels. The company is focused on firms in emerging, high growth technologies and solutions in machine to machine applications and technologies and cloud-based software as a service business applications.

The enterprise sells their products and services through its distribution channels and is also involved in negotiating distribution agreements with relevant organizations. It also provides stolen vehicle recovery, asset tracking and IoT inventory management solutions to the automotive dealership industry. Its services are delivered via the AWS Cloud to consumers over wireless networks, which can be accessed from any desktop or mobile device. The enterprise’s software services are marketed through automotive dealers, government channels and financial institutions as distinct consumer and commercial brands, which include Medallion GPS PRO, CU Trak and Nimbo Tracking.

The company recently launched a nationwide Dealership Program between the Peak Performance Team and Nimbo Tracking. This opportunity will develop a comprehensive program that takes advantage of the company’s services and products across multiple consumer segments, which will be good for investments into the company.

iGen Networks Corp (IGEN), closed Friday's trading session at $0.012, up 33.3333%, on 130,594,449 volume with 1,980 trades. The average volume for the last 3 months is 130.558M and the stock's 52-week low/high is $0.0029/$0.0243.

Aldeyra Therapeutics (ALDX)

MarketBeat, MarketClub Analysis, StockMarketWatch, BUYINS.NET, RedChip, TraderPower, Kiplinger Today, Marketbeat.com, Promotion Stock Secrets, Wall Street Mover, PoliticsAndMyPortfolio, InvestorPlace, Schaeffer's, Barchart, Short Term Wealth, StockOodles, StreetInsider, TopPennyStockMovers, Trades Of The Day and Red Chip reported earlier on Aldeyra Therapeutics (ALDX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) (FRA: 137) is a biotechnology firm that is focused on the development and commercialization of medicines for systemic and immune-mediated ocular ailments.

The firm has its headquarters in Lexington, Massachusetts and was incorporated in 2004, on August 13th by John E. Dowling and Thomas A. Jordan. Prior to its name change in March 2014, the firm was known as Aldexa Therapeutics Inc. It serves consumers in the United States.

The company’s objective is to develop new products for orphan, inflammatory, immune-mediated and other illnesses that may be caused partly by toxic chemical species which occur naturally, known as free aldehydes.

The enterprise’s product pipeline is made up of a di-hydrofolatereductase inhibitor known as ADX-2191, which is undergoing phase 2 clinical trials testing its effectiveness in treating primary vitreo-retinal lymphoma and in phase III trials for the prevention of proliferative vitreo-retinopathy. It also develops an ophthalmic solution dubbed reproxalap, which is in a phase 2 clinical trial evaluating its efficacy in treating allergic conjunctivitis and dry eye ailments. In addition to this, it develops a small molecule heat shock protein 90 inhibitor known as ADX-1612, to treat lymphoproliferative illnesses and reactive aldehyde species that are pro-inflammatory scavengers. It also develops ADX-103 to treat retinal ailments; and ADX-629 to treat allergies and autoimmune ailments.

The firm recently announced its latest financial results for 2021, with its CEO noting that they were focused on advancing the development of effective and safe treatments for systemic and ocular ailments that will improve the lives of patients whose needs haven’t been met.

Aldeyra Therapeutics (ALDX), closed Friday's trading session at $6.93, off by 1.7021%, on 478,870 volume with 4,415 trades. The average volume for the last 3 months is 469,638 and the stock's 52-week low/high is $6.47/$15.95.

Lordstown Motors Corp. (RIDE)

Green Car Stocks, Schaeffer's, InvestorPlace, The Street, MarketBeat, MarketClub Analysis, Trades Of The Day, StocksEarning, Daily Trade Alert, CNBC Breaking News, The Online Investor, Early Bird, StreetInsider, BUYINS.NET, The Stock Dork, Cabot Wealth and QualityStocks reported earlier on Lordstown Motors Corp. (RIDE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alabama Governor Kay Ivey recently launched an electric vehicle (“EV”) campaign that will see the Southern state join the growing number of states with electrification plans. Under an EV education and marketing campaign, dubbed Drive Electric Alabama, the state will promote awareness about electric vehicles and increase the number of public EV charging stations.

Charging has always been a hindrance to EV adoption because it exacerbates range anxiety, but Alabama is hoping to develop a wide charging infrastructure network right off the bat.

Ivey was joined by the director of the Alabama Department of Economic and Community Affairs (“ADECA”) Keneth Boswell, Alabama Clean Fuels Coalition President Michael Staley, and state reps Anthony Daniels and Danny Garrett at the unveiling of the Drive Electric Alabama program. Speaking at an EV charging station at the University of Alabama, Ivey said that with automakers investing billions of dollars into electric vehicles, Alabamians are bound to start thinking about buying EVs. Consequently, the new education and marketing program would help residents of the state learn all they need to know about electric vehicles.

Boswell declared that electric vehicles are the next evolution of automobile manufacturing and that it was the perfect time for Alabama residents to learn about them. The program will involve educational events such as ‘ride and drive’ for customers to provide an idea of electric vehicle functionality and fuel savings, says Stanley. With automakers, including Alabama’s own Mercedes-Benz, increasingly adding electric vehicles to their line-ups and more drivers going electric, Stanley says that electric vehicles are past the early-adopter stage. The Alabama Clean Fuels Coalition is currently working with partners and lawmakers to develop a comprehensive EV strategic plan for Alabama, he says.

Birmingham resident Adriene Holmes talked about her 2016 Chevrolet Spark during the launch, saying that it had low running costs, fewer parts to break down and maintain, and savings on gas. The transition from an internal combustion engine (“ICE”) car to a battery-electric one was “wonderful and painless,” she reported.

State Rep. Anthony Daniels is already planning on getting an EV for himself in the near future. He mentioned that he would take advantage of the frunk, which is the empty space where an engine would have been, to take family trips to the beach.

The Drive Electric campaign will feature radio, television and digital advertising. It will also include billboards and events designed to increase awareness about electric vehicle technology, charging and affordability.

As elected leaders such as Ivey shoulder the responsibility of creating a suitable environment for electric vehicle uptake to accelerate, manufacturers in this sector such as Lordstown Motors Corp. (NASDAQ: RIDE) can look forward to a promising future.

Lordstown Motors Corp. (RIDE), closed Friday's trading session at $4.16, off by 1.1876%, on 3,467,637 volume with 16,160 trades. The average volume for the last 3 months is 3.464M and the stock's 52-week low/high is $3.58/$31.5678.

LSB Industries, Inc. (LXU)

VectorVest, SmarTrend Newsletters, StockMarketWatch, StreetInsider, QualityStocks, TradersPro, MarketBeat, Zacks, MarketClub Analysis, BestOtc, Marketbeat.com, CRWEWallStreet, DrStockPick, PennyOmega, StockHotTips, CRWEFinance, PennyToBuck, CRWEPicks, Market FN, Money and Markets, Schaeffer's, The Best Newsletters, TopStockAnalysts, Rick Saddler, INO.com Market Report, CrashTrade, BUYINS.NET, BestChartNow, Barchart, Dynamic Wealth Report, Hit and Run Candle Sticks, Investing Futures, InvestorPlace, Investors Alley, Market Wrap Daily, Alternative Energy, MegaPennyStocks, PoliticsAndMyPortfolio, StreetAuthority Daily, Super Stock Picker, Traders For Cash Flow, Wall Street Greek, Weekly Wizards and MarketWatch reported earlier on LSB Industries, Inc. (LXU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LSB Industries, Inc. (NYSE: LXU) was featured in a company-sponsored research note published by Sidoti & Company, LLC. The headline of the note reads, “Management Offers Positive Outlook At Our Conference, Highlights Potential Of Blue And Green Ammonia; Maintain $12 Price Target And Note Improved Balance Sheet, High Ammonia Prices.”

Click here to access the full report.

About LSB Industries, Inc.

LSB Industries, headquartered in Oklahoma City, Oklahoma, manufactures and sells chemical products for the agricultural, mining, and industrial markets. The Company owns and operates facilities in Cherokee, Alabama, El Dorado, Arkansas and Pryor, Oklahoma, and operates a facility for a global chemical company in Baytown, Texas. LSB’s products are sold through distributors and directly to end customers primarily throughout the United States. Please visit www.lsbindustries.com.

LSB Industries, Inc. (LXU), closed Friday's trading session at $9.37, up 2.967%, on 245,943 volume with 2,926 trades. The average volume for the last 3 months is 243,696 and the stock's 52-week low/high is $1.408284/$10.86.

The QualityStocks Company Corner

SPYR Inc. (OTCQB: SPYR)

The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.

Products

The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Friday's trading session at $0.05835, up 32.6136%, on 78,473 volume with 16 trades. The average volume for the last 3 months is 78,473 and the stock's 52-week low/high is $0.0321/$0.231.

Recent News

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF)

The QualityStocks Daily Newsletter would like to spotlight Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF).

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF) (FRA: 7CR) is positioned to take a significant share of the growing online gambling market by offering a first-rate experience while ensuring total user privacy. Analysts at Research and Markets expect this space to grow at a CAGR of 11.94% between 2021 and 2026, while Grand View Research projects that it will reach $127.3 billion by 2027, with much of that growth coming from the United States and Asia. “PLGNF provides an innovative multitenant gateway that enables online operators to offer users popular games… The company’s proprietary software combines high-definition live streaming dealers with state-of-the-art augmented reality betting to provide an authentic casino experience based in Las Vegas. In addition, the company’s privacy-enhanced software enables seamless integration at the operator level while allowing users to access the platform without sharing sensitive data or requiring an app store download,” explains a recent article. “With a portfolio of IP-protected assets and high barriers to entry, the company is positioned favorably within the rapidly growing iGaming industry.” To view the full article, visit https://ibn.fm/cJF0N

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) is a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market. The company provides a multi-tenant gateway that allows online operators the ability to offer their customers innovative iGaming software solutions. Its current software platform includes Live Dealer Casino, E-Table Games and Daily Fantasy Sports. Seamless integration at the operator level allows customer access without requiring the sharing of any sensitive customer data. Playgon games run on any browser and any device as fast and secure as a native app, without requiring any app store download. All that’s needed is a stable internet connection. The gaming experience is identical across all mobile devices. As a true business-to-business digital content provider, the company’s products are scalable turnkey solutions for online casinos, sportsbook operators, location-based operators, media groups, and big database companies.

Playgon’s proprietary technology provides digital games for online gambling sites and mobile device apps, with the company licensing its mobile live-dealer technology to online gaming operators worldwide. Playgon combines high definition live streaming dealers with state-of-the-art augmented reality betting to provide the most authentic casino experience, live from Las Vegas. Playgon’s mobile platform features popular table games, all optimized for one-handed play on mobile devices.

The COVID-19 pandemic has accelerated an already existing shift away from location-based casinos to online gambling. At the same time, the proliferation of mobile devices has provided players with new access to betting. A younger, tech-savvy consumer demographic is driving adoption of digital gaming globally. To meet this demand, Playgon has launched a studio with 10 gaming tables from which its live dealer streaming video originates. The company’s platform is live with multiple online casino operators through four aggregator clients in South Africa and Europe, and commitments are coming in from more.

Playgon plans to expand the studio to 25 tables in the near term and is working to establish a U.S. strategy. The company will continue to expand licensing of its live dealer games to iGaming operators worldwide under a SaaS license agreement. As a B2B software supplier, Playgon avoids player acquisition costs.

Games

Live Dealer Casino

Playgon offers the first and only Live Dealer Casino streaming live from Las Vegas. The company brings cutting-edge handheld features and functionality to the mobile generation of gaming enthusiasts who demand a world-class gaming experience on all devices. Playgon’s Blackjack delivers the look and feel of location-based casino tables with features providing players with the most unique user experience. The company’s true-to-life Roulette offers players a clear and uninterrupted view of the dealer, wheel, ball, bets, results, trends and statistics. Players can strategize, place multiple bets, track results and review trends without ever losing focus of the game.

Playgon’s traditional Baccarat and proprietary Tiger Bonus Baccarat™ prove their worth by not only recognizing the need for a prominent product, but by adding elements which separate them from the pack without removing their authenticity. The games mix advances in technology with the traditional game attributes that have resonated and captivated players for hundreds of years.

eTable Games

To lead the rise of mobile-first gaming, Playgon developed a user experience perfected for one-handed play. Providing this next evolution in gaming technology ensures the company’s client operators loyalty from existing customers and is a powerful strategy to attract and retain new players. Playgon’s VEGAS LOUNGE™ brings together an innovative mix of games, technology and gameplay that offers players an authentic experience and real Las Vegas casino fun every time, everywhere.

Daily Fantasy Sports

Playgon’s Daily Fantasy Sports (DFS) are a subset of fantasy sport games which typically target a younger demographic. DFS provides iGaming operators a turnkey fantasy sports platform that can quickly go to market, integrate with the operator’s existing operations and services, and be customized to match and enhance the operator’s brand. The platform is mobile and desktop friendly, built for regulated market environments, and allows operators to monetize users through a network of shared liquidity.

Market Outlook

Online casinos and sports betting sites/apps are increasingly adding market share to traditional location-based casinos. This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, as well as tech like digital wallets and digital gameplay that underpins Playgon Games. The company has been described as “Netflix + Vegas, all in one.”

The online gambling market is slated to reach a value of $127.3 billion by 2027, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25 percent year over year. The current global online Live Casino TAM is estimated at about $6 billion annually, and revenue is forecast to reach more than $8 billion by 2023 and more than $13 billion by 2027.

Management Team

Darcy Krogh is CEO of Playgon Games. He is a veteran of the iGaming industry with over 20 years of experience. In 1999, he co-founded Chartwell Technology Inc., which pioneered the development of browser-based digital content for the iGaming industry. After that company was sold to Amaya Gaming Group, he served as VP Business Development with Amaya. In 2016, he started Playgon Games (formally Global Daily Fantasy Sports Inc.) as President and CEO. His experience in the online gaming industry includes sales and marketing, relationship management, corporate finance, M&A, and strategic corporate development.

Guido Ganschow is President of Playgon Interactive. He has more than 12 years of experience in creating real-time Live Dealer technology and platforms and was the co-founder and Creative Director for a Macau-based casino consortium. Between 2008 and 2014, he successfully created and established Live Dealer platform businesses in Asia and Europe, and executed commercial partnerships, sales, and integration of the Live Dealer solution with major global gaming brands, including Ho Gaming Group, Chartwell Technology and Amaya Gaming Group.

Steve Baker is COO of Playgon. He is a former VP Operations for Shaw Communications, where he was directly involved in video streaming, home entertainment, new products, sales and M&A. He oversaw revenue growth from $300 million to $2.8 billion and employee growth from 350 to 13,000. He has broad experience and a proven record in development and implementation of cost effective and efficient growth strategies transitioning businesses from development to operations.

Harry Nijjar is CFO of Playgon Games. He is currently a Managing Director with Malaspina Consultants Inc. and provides CFO and strategic financial advisory services to his clients across many industries. This experience has allowed him to help his clients successfully navigate the regulatory and financial environments within which they operate. Mr. Nijjar holds a CPA-CMA designation from the Chartered Professional Accountants of British Columbia.

Playgon Games Inc. (PLGNF), closed Friday's trading session at $0.28, up 8.4011%, on 3,500 volume with 5 trades. The average volume for the last 3 months is 3,500 and the stock's 52-week low/high is $0.197/$0.6282.

Recent News

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Last week, the price of gold increased as the market tried to figure out the possible effect of the weak U.S. jobs report on the Fed’s monetary policy. This comes as the new coronavirus variant, dubbed omicron, continues raising uncertainty in the economy. In New York, U.S. gold futures rose on Friday by 1% to reach $1,780 per ounce. By 12:15 p.m. ET, spot gold was up by almost 1%, reaching $1781. 60 per ounce, avoiding another weekly loss. Earlier that day, the Bureau of Labor Statistics had reported that only 210,000 jobs were created in November, which is significantly lower than what economists expected. It was expected that in the month of November, about 530,000 jobs would be created. Nonetheless, precious metals sector players such as Asia Broadband Inc. (OTC: AABB) are likely to see this uncertainty as a simple blip since their long-term plans factor in such fluctuations resulting from market sentiment.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Friday's trading session at $0.1955, up 11.0165%, on 34,204,018 volume with 1,994 trades. The average volume for the last 3 months is 34.204M and the stock's 52-week low/high is $0.0035/$0.659.

Recent News

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF)

The QualityStocks Daily Newsletter would like to spotlight Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF).

  • MINDCURE President and CEO Kelsey Ramsden will participate in, and has already attended multiple industry conferences throughout December
  • Participation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelics
  • Company remains focused on promoting healing and improving mental health via digital therapeutics technology and psychedelic compounds research
  • Company reports that 971 million people worldwide suffer from a mental disorder. As of 2019, MINDCURE calculates that 12,472 registered mental health facilities treatment facilities could benefit from the company’s proprietary digital therapeutics technology, iSTRYM
  • The global digital therapeutics market is valued at $3.4 billion and is projected to reach $13.1 billion by 2026, primarily driven by the growing need for control over healthcare costs and the rising focus on preventative health opportunities

Life sciences company Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) a leader in advanced proprietary technology and research for psychedelics, is rounding out 2021 by participating in the Life Sciences Investor Forum, a virtual investor conference that provides a fully interactive forum where publicly-traded companies can meet and present directly to investors. President and CEO of MINDCURE, Kelsey Ramsden, will be presenting virtually during the Life Sciences Investor Forum – which will be available archived on the conference’s website after the event has concluded (https://ibn.fm/q34CM). The virtual forum will take place on December 16, 2021, with MINDCURE presenting at 11:30 AM EST.

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health.

MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per year, psychedelics offer promising alternatives for healing. This medical need has been amplified by the COVID-19 pandemic. According to the Centers for Disease Control and Prevention, 40 percent of U.S. adults reported struggling with substance abuse or mental health issues during the pandemic.

MINDCURE is uniquely positioned to address these medical needs. By concentrating on both technology and research, the company is focusing on near-term revenue generation, targeting a longer-term, blue sky horizon and hedging against regulatory unknowns with a scalable, adaptive model. MINDCURE’s software-as-a-service (SaaS) platform, iSTRYM, scales globally and services every psychedelic medicine without the capital-intensive drag of clinic scale-out costs. The company plans to first enter the market for psychedelic-assisted psychotherapy, then to move into the larger fields of technologically undisrupted psychotherapy and psychiatry.

Technology

Digital therapeutics include health interventions delivered through a smart device to induce a behavioral change in the patient. The global market is focused on simplifying behavioral change and empowering consumers to take charge of their own health. iSTRYM is the company’s AI-driven software platform that enables personalized and quantified outcomes in psychedelic therapy. The SaaS platform modernizes care, taking it from manual to digital and bringing better treatment outcomes for patients and therapists while lowering costs for insurers.

iSTRYM offers clinicians direct access to global, science-backed, evidence-based protocols, integration plans, insights into client journeys, and real-time assessments for personalized care. Patients access the platform on their smart devices, enjoying transparency into their wellness journeys, personalized care resources, and optimized relationships with their practitioners. The minimal viable product (MVP) of the software is being launched in Q3 2021. MINDCURE targets a Q1-Q2 2022 commercial product launch.

Research

In June 2021, the company announced it had completed the first stage of manufacturing pharmaceutical-grade synthetic ibogaine to be used in clinical research. In July, MINDCURE announced it had filed U.S. Provisional Patent applications for the company’s first full synthetic routes to create ibogaine. The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.

The company is also actively researching ibogaine as a potential treatment for Traumatic Brain Injury and related conditions. Preliminary data show the drug may also have promise as a treatment for neuropathic pain and migraines. In addition, research indicates ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addictions.

Market Outlook

MINDCURE actively develops technology, conducts research, and distributes products in several market spaces. The global market for digital therapeutics is projected to grow to $6.9 billion by 2025, from an estimated $2.1 billion in 2020. In North American alone, the market is forecast to reach $5 billion by 2025.

The market for treatment of drug, alcohol and other addictions is estimated to be worth $38.2 billion in 2021, with a forecast CAGR of 5.2 percent for the next several years. The global market for the treatment of neuropathic pain is forecast to account for $9 billion by 2027, while drug treatment for migraines is expected to have a value of $2.1 billion by 2025.

Management Team

Kelsey Ramsden is President and CEO of MINDCURE. She has 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple eight-figure businesses and twice been named Canada’s Top Female Entrepreneur. She holds a seat on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. She has an MBA from the Richard Ivey School of Business at the University of Western Ontario.

Dr. Joel Raskin is the Chief Medical Officer at MINDCURE. He is a psychiatrist and academic with 20 years international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch and commercialization with Eli Lilly & Co., where, as Senior Director, he led the medical affairs team for Alzheimer’s disease diagnostics and therapeutics. He earned his medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada in Psychiatry.

Tarik Lebbadi is the COO at MINDCURE. He has more than 13 years of international operational experience. Before joining the company, he led the medical division of Johnson & Johnson in Morocco. He holds a BA in mathematics and computer science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.

Geoff Belair is the CTO at MINDCURE. He has 30 years of experience working in highly regulated industries, including fintech and banking. He was the senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Before joining MINDCURE he was Vice President of Information Technology at Westland Insurance.

Michael Wolfe, CPA CA, is MINDCURE’s CFO. He has 30 years of experience in finance, accounting, private equity, and business valuation. He was previously CFO of Baylin Technologies Inc., as well as CFO of several mid-market Canadian companies, including Masstech Group Inc. He was General Partner at VenGrowth Capital Partners Inc. He holds an MBA from McMaster University and a BA in business and economics from the University of Western Ontario.

Daniel Herrera is Vice President of Growth & Strategic Partnerships at MINDCURE. He is a former pharmaceutical executive with extensive experience in highly regulated industries. He is experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, as well as strategic partnerships resulting in high-value M&A transactions. He is a graduate of McGill University and the University of Montreal and holds an MBA from the John Molson School of Business at Concordia University.

Mind Cure Health Inc. (OTCQX: MCURF), closed Friday's trading session at $0.182, up 3.4444%, on 97,699 volume with 29 trades. The average volume for the last 3 months is 97,699 and the stock's 52-week low/high is $0.1596/$0.8584.

Recent News

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF)

The QualityStocks Daily Newsletter would like to spotlight Mydecine Innovations Group Inc. (MYCOF).

  • The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin
  • In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea
  • Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing and strategic advancements
  • Company intends to uplist to NASDAQ in Q1 2022

Improving delivery control and shelf stabilization of psilocybin’s active metabolite psilocin, two critical aspects for use in medical settings, is the key goal of a new patent application filed by Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotech and digital technology company focused on transforming the treatment of mental health and addiction disorders. The full patent application Mydecine filed covers multiple families of psilocin analogs, according to a company press release. In a notice that was recently published in the Federal Register, the Drug Enforcement Agency (“DEA”) revised upwards its 2022 quota for the production of illicit controlled substances, such as DMT, MDMA and psilocybin, for research purposes. The agency adjusted its quota once again for these psychedelic substances, in response to the increased demand and interest in the scientific community. As more entities conduct research on psychedelic substances, the therapeutic formulations developed by companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) will have plenty of literature backing them up.

Mydecine Innovations Group Inc. (NEO: MYCO) (NASDAQ: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction. Founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovations in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics to treat PTSD, addiction and other mental health disorders.

Mydecine’s business model combines clinical trials and data outcome, technology and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine aims to responsibly fast-track the development of new medicines across its platforms, ultimately changing the way we treat mental health disorders. The company seeks to bridge the gap between the needs of patients and what the mental health care system currently provides.

Mydecine Innovations Group is headquartered in Denver with international offices in Canada and Europe.

Research and Technology

The invention and development of novel psychedelic and non-psychedelic molecules for medical use is an important part of Mydecine’s research strategy. The company uses molecules found in nature as building blocks to create improved second-generation drugs. This portfolio of new drugs represents major improvements to existing natural products and synthetics, including enhanced safety, efficacy, stability and dosing, as well as reduced side effects.

The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients, along with improved management of dosage and drug behavior for clinicians. Mydecine believes the multibillion-dollar market for mental health and addiction disorder medicines will soon be disrupted amid a resurgence of the study into psychedelics and data showing the immense benefits of these forms of medicine.

The company currently has four lead drug candidates which include various enhancements such as improved controllability, delivery mechanisms, safety, stability and shelf-life. The drug candidates are in clinical trials or in pre-trial stage as potential treatments to aid PTSD, substance abuse and smoking cessation.

Mindleap Health is a wholly owned subsidiary of Mydecine. The Mindleap platform is a virtual community that aims to foster the conscious and responsible adoption of psychedelic medicine into inner wellness. Users access the platform through the Mindleap app. Mindleap provides users with inner wellness resources to assist them in their daily mental-health journeys. The platform also seeks to support the conscious and trustworthy adoption of psychedelics into a widely accepted approach to mental health and inner wellness.

Market Outlook

The global smoking cessation market is expected to reach $63.99 billion by 2026, growing at a CAGR of 16.9 percent from 2018 to 2026. The market for psychedelic therapeutics is in its very early stages. Estimates of current market value and forecasts of expected value in future years are all over the map. Market forecasts range from $6.5 billion by 2030 with a CAGR of 15 percent, to more than $69 billion as soon as 2025, at a CAGR of 8.2 percent. What is clear is that interest in psychedelic therapeutic drugs is expanding rapidly.

Management Team

Joshua Bartch is Chief Executive Officer and Chairman of Mydecine Innovations Group. He is an experienced entrepreneur who co-founded AudioTranscriptionist.com and founded Denver-based dispensary Doctors Orders in 2009. He also founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the USA’s most significant and sophisticated legal cannabis wholesale platform.

Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, is the Chief Medical Officer of Mydecine. He was formerly Chief of Psychiatry for the Canadian Armed Forces, retiring in 2021 with the rank of colonel after 31 years of service. He began his career as a general duty medical officer and flight surgeon and spent his final 20 years of service as a psychiatrist. He maintains academic appointments at Dalhousie University and The University of Ottawa. He is the inaugural CF Brigadier Jonathan C. Meakins CBE, RCMAC, Chair in Military Mental Health at the Royal Ottawa Hospital.

Robert Roscow is Chief Scientific Officer of Mydecine. As a geneticist, he has spent his academic and professional careers looking for valuable and unique medicinal molecules found in nature. His innovations were applied at Canopy Growth and ebbu, where he ran those companies’ genetics divisions. He has leveraged his expertise to maximize industrial production of cannabinoids in a pharmacological context, resulting in multiple patent filings.

Damon Michaels is Chief Operating Officer of Mydecine. He previously consulted for various hemp businesses through his company, Emerald Baron. Before that, he served as GM for ebbu, the leading multi-platform cannabinoid research and technology firm based in Colorado. He has held leading roles with multiple large brands throughout the cannabis vertical. He also developed a national snowboard brand.

Mydecine Innovations Group Inc. (MYCOF), closed Friday's trading session at $0.1373, up 6.4341%, on 710,415 volume with 239 trades. The average volume for the last 3 months is 710,415 and the stock's 52-week low/high is $0.01/$2.20.

Recent News

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) CEO and other key leaders will be hosting a year-end update call. The call, which will be held on Dec. 15, 2021, at 1 p.m. ET, will also include a discussion about the company’s growth strategy looking forward. According to the company, the one-hour call will include opening remarks, and overview presentation and update, and a Q&A session. Avricore Health is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. “We’ve had our best year yet, despite many external factors that created headwinds, and we’re extremely excited to head into 2022,” said Avricore Health CEO Hector Bremner in the press release. “Given that we are well capitalized and have executed several key agreements already, we’re well positioned for growth.” To view the full press release, visit https://ibn.fm/xP456

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Friday's trading session at $0.10685, even for the day. The average volume for the last 3 months is 5 and the stock's 52-week low/high is $0.068/$0.48562.

Recent News

RYAH Group Inc. (CSE: RYAH)

The QualityStocks Daily Newsletter would like to spotlight RYAH Group Inc. (CSE: RYAH).

Dozens of states may have legalized medical marijuana, but the federal government still classifies cannabis as a Schedule I Controlled Substance with no known medical applications. For years, two federal agencies have clashed over which of them should determine marijuana’s medical potential by running an independent, peer-reviewed study on the potential health benefits of cannabis consumption. With no end to the disagreement in sight, a libertarian think tank has sent a letter to the White House Office of Management and Budget (“OMB”) asking it to clear the issue. Once that review is completed, chances are that cannabis could be removed from the most restrictive CSA category and more patients would be willing to use advanced plant medicine devices such as the RYAH Smart Inhaler made by RYAH Group Inc. (CSE: RYAH).

RYAH Group Inc. (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.

Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.

Product Portfolio

The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

RYAH Smart-Inhaler

The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.

RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.

In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.

RYAH Smart-Patch

The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.

RYAH Smart-Pen

The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.

RYAH MD

RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.

PotBot App

The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.

Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.

Market Outlook

RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.

In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ).

Management Team

Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.

Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.

RYAH Group Inc. (CSE: RYAH), closed Friday's trading session at $0.045, even for the day, on 125,700 volume with 13 trades. The average volume for the last 3 months is 707,627 and the stock's 52-week low/high is $0.04/$0.20.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022
  • The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications
  • Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral nicotine delivery

Diabetes, rheumatoid disease, Alzheimer’s Disease, and estrogen delivery, are some of the multiple indications that drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) is planning to target with its research and development programs next year. The markets targeted provide multiple opportunities for success and are now expected to reach an overall estimated value of more than $160 billion annually, worldwide over the next few years. 

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $4.94, off by 0.803213%, on 287,502 volume with 1,891 trades. The average volume for the last 3 months is 287,502 and the stock's 52-week low/high is $3.9751/$12.50.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, has made available key presentations from its Sequire Clean Tech & Electric Vehicles Conference. The premier virtual investor event was held on Dec. 6, 2021, and featured presentations from more than 25 elite stock market companies that are leading the way in the clean-tech space; the event also included insightful addresses and discussions with industry execs looking at the future of clean tech. Topics covered electric vehicles, energy and power, and materials and chemicals. Replays of the keynote addresses and company presentations are available on the event website for three months. To view the presentations, visit https://ibn.fm/JbYnU. To view the full press release, visit https://ibn.fm/IeI9l

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Friday's trading session at $4.36, off by 0.683371%, on 32,105 volume with 462 trades. The average volume for the last 3 months is 32,105 and the stock's 52-week low/high is $2.42/$7.29.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Diabetes is a common disease, with figures showing that about 6% of the global population is afflicted by the ailment. Since 1990, rates of the disease have been increasing, with estimates showing that this trend is expected to continue for at least two more decades. Now new research has found that type 2 diabetes is more common in individuals with psychiatric disorder, in comparison with other people. The research was carried out by a team of researchers from the University of Southern Denmark, led by Nanna Lindekilde of the school’s psychology department. Its findings were reported in “Diabetologia.” The study clearly shows how vital it is to address psychiatric disorders as soon as possible before additional complications set in, and that is why the work of companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), which are developing new medicines targeting mental disorders, deserve any support available.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Friday's trading session at $1.2, off by 0.826446%, on 1,515,848 volume with 3,864 trades. The average volume for the last 3 months is 1.507M and the stock's 52-week low/high is $0.95/$3.38.

Recent News

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC)

The QualityStocks Daily Newsletter would like to spotlight AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC).

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its joint technical paper on novel Cancer Differentiation Analysis (“CDA”) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online. The piece was published on Nov. 30 by the Expert Review of Molecular Diagnostics, a peer-reviewed international medical journal that has an impact factor of 5.2. “We are very pleased with the publication of our technical paper on CDA cancer detection technology by a peer-reviewed international journal in the field of medicine,” said Dr. Chris Yu, AnPac Bio’s chairman and CEO. “The review and subsequent acceptance of our paper based on the novel and original biophysics-based CDA cancer detection technology for publication is very gratifying and indicates what we believe is a positive level of recognition for this approach. The findings reported in this study validates the CDA technology and has laid both the conceptual and practical groundwork for CDA technology to be used in large population cancer screening. We will continue to invest in research and development and, at the same time, speed up our commercialization process.” To view the full press release, visit https://ibn.fm/oT3T1

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.

AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.

Cancer Differentiation Analysis (CDA)

Cancer Differentiation Analysis (CDA) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.

Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.

CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.

AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.

Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

  • Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
  • Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
  • Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
  • Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
  • Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
  • Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook

AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.

According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://nnw.fm/L7css). The market is expected to grow at a CAGR of 7% during the forecast period.

Management Team

Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.

Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.

Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

AnPac Bio-Medical Science Co. Ltd. (ANPC), closed Friday's trading session at $1.19, off by 7.7519%, on 457,130 volume with 1,583 trades. The average volume for the last 3 months is 457,130 and the stock's 52-week low/high is $1.15/$12.09.

Recent News

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF)

The QualityStocks Daily Newsletter would like to spotlight PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF).

  • PlantX is celebrating the expansion of its e-commerce platform to the United Kingdom
  • The platform will offer a wide array of plant-based products, indoor plants, and educational resources
  • The UK is the leading market for plant-based alternatives in Europe and has in the recent past witnessed changes that align perfectly with PlantX’s recent move
  • The launch of the site fulfills the company’s mission and is a step in the right direction for the PlantX

In line with its mission of bringing more plant-based options to as many people as possible, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has announced the expansion of its e-commerce platform to the United Kingdom (“UK”). Set to be launched under the domain www.PlantX.uk, the new platform will offer customers a similar experience as PlantX’s customers in Canada and the United States have become accustomed to (https://ibn.fm/o5a3e).

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based community through e-commerce, with a core objective of becoming the most trusted and convenient destination for people living plant-based lives. PlantX is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, connecting consumers with interactive PlantX brick-and-mortar stores, and a PlantX home delivery system for products, meals, recipes and more.

PlantX is a high-growth technology company focusing on consumer-packaged goods (“CPG”) for the plant-based opportunity. The PlantX platform aims to serve as the digital face of this community with its one-stop-shop for everything plant-based, including:

  • An easy-to-use e-commerce shopping experience featuring the following:
    • Plant-based grocery items (from all your pantry needs to vitamins, cosmetics and even pet food)
    • Meal delivery with recipes created by well-known plant-based chefs throughout the world
    • Plant shop – delivering a wide variety of affordable indoor houseplants to homes across Canada and the U.S.
    • Easy to follow plant-based recipes every week
    • Partnerships with restaurants, nutritionists, chefs and brands
    • A community of like-minded individuals
  • State-of-the-art flagship PlantX locations

Since first launching in February 2020, PlantX Life has offered various services available through its comprehensive platform. This online marketplace features over 10,000 items across diverse product categories such as pantry items, beverages, personal care, pet food and indoor plants. In addition, PlantX has collaborated with renowned chefs and nutritionists to create 20 unique and pre-made meals delivered to the comfort of your own home.

Headquartered in Vancouver, Canada, PlantX’s mission is to spearhead the plant-based movement, celebrate and promote health and wellbeing, raise plant-based awareness in a hyper-palatable world, connect with global consumers and forge a welcoming plant-based community.

The company currently reports 4 million stock options and 24 million warrants outstanding, with a total of 88,832,159 shares issued and outstanding and a total market cap of $89.9 million on January 18, 2021. PlantX has continued to catalyze its capital markets dynamics by applying to list its common shares on the Nasdaq Capital Market (“NASDAQ”). The company’s common shares are eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States.

Market Outlook

With its comprehensive e-commerce platform, PlantX is strongly positioned for a prominent role in the fast-growing plant-based food market, e-commerce and the online food delivery sectors. The global plant-based food market is expected to reach $74.2 billion by 2027, expanding at a CAGR of 11.9%. Similarly, the online food delivery market has steadily grown, especially during the current pandemic. This trend seems here to stay. In the United States alone, the sector is expected to report $28.5 billion by 2024, with companies such as UberEats experiencing 152% increases in food deliveries in the summer of 2020.

Complementary to these trends, and as a result of the COVID-19 pandemic, online sales and digitization have also both grown exponentially in 2020. Grocery shopping has seen a remarkable transition to e-commerce, with online grocery sales growing by 53% in 2020. Amid the pandemic-imposed physical interactions and related consumer behavior change, large retailers have been compelled to meet this surge in e-commerce demand. For example, Whole Foods Markets has increased its online sales capacity by over 60% in 2020. The global meal kit delivery system is also becoming increasingly popular and is expected to achieve a market value of $19.92 billion by 2027, expanding at a CAGR of 12.8%.

PlantX aims to capitalize on this anticipated exponential market growth of the plant-based, e-commerce and home-delivery industries.

Digital Platform for the Plant-Based Community

The digital interface provided by PlantX spans a health and wellness initiative that offers thousands of plant-based products, meal delivery, indoor plants, recipes and a community space for those who are like-minded about plant-based products and healthy lifestyles. PlantX has been compared to Amazon, except with a focused tailored selection of plant-based offerings.

PlantX provides everything a consumer needs for plant-based living at the click of a button. With PlantX, customers can:

  • Shop
  • Find recipes
  • Read blogs
  • Join a community forum
  • Listen to podcasts
  • View cosmetics
  • Research vitamins
  • Purchase plant-based pet foods
  • Read corporate updates
  • Subscribe to an insightful newsletter

The company’s website was designed with a user-friendly interface that allows customers to visit the site and easily find what they need. Forums for communicating with a plant-based community make it easier to swap recipes or locate the best restaurants serving vegan and vegetarian-friendly cuisine.

PlantX Flagship Locations – British Columbia (Canada), San Diego (California), & the State of Israel

PlantX will link the e-commerce platform to flagship brick-and-mortar stores for a highly sensory customer experience. This is anticipated to drive corporate growth and global brand recognition.

These PlantX branded flagship locations will first launch in:

Customer engagement, education and creating a global plant-based community will be furthered through this initiative.

PlantX Restaurant Partnerships

With consumers becoming better informed and more health and environmentally conscious, a growing number of restaurants will start catering to the needs of customers who are vegan, vegetarian, have food-allergies (or specialized diets), or simply want to eat healthier.

PlantX proactively aims to support this change and help restaurants meet the needs of the plant-based community. Restaurants that want to increase revenue, drive traffic and make an impact can therefore partner with PlantX to better serve their customers by expanding and refining their menus.

Future Goals for PlantX Life

Having successfully completed all of the milestones that PlantX had set-out to achieve in the second half of 2020, PlantX strives to continue scaling through organic growth, strategic partnerships and accretive M&A opportunities. The upcoming plans from PlantX includes a global expansion strategy for distribution in North America, Europe and Israel.

Verticals launched in 2020 include:

  • New meals and programs by renowned chefs
  • Flagship PlantX locations
  • PlantX branded goods
  • United States meal delivery and LIV
  • Online peer-to-peer fitness

Management Team

Sean Dollinger, the Founder of PlantX Life Inc., has had a very active professional career that started when he was only 17. While still in college, he started a delivery service that soon became one of Canada’s largest delivery firms (before companies like Postmates and Uber Eats ever existed). In 2014, Mr. Dollinger founded Namaste Technologies, the largest international e-commerce distributor of vaporizers and accessories. He brought Namaste public and turned it into a $1.2 billion business in two years. After finding a plant-based diet himself, and seeing the massive benefits that it provided for him, he decided he wanted to find a way to give back to the community and focus on something he loves. PlantX Life was born from this desire and became his passion project. He truly walks the talk.

Julia Frank is the CEO of PlantX Life. She has an MBA in digital entrepreneurship, and, in her past roles, she set up renowned strategies for large corporations like BMW and Daimler in Germany. Beyond her professional business prowess, Ms. Frank finds tremendous joy in preparing delicious and nutritious plant-based meals and is the face of the company. She practices a healthy and active lifestyle that includes experiencing as many cultures as possible to add more knowledge of the industry at large. This globally inclusive perspective gives her the unique advantage of being able to see plant-based living from all angles.

Lorne Rapkin, CPA, CA, LPA, is the President and CFO of PlantX Life and is also a partner at Rapkin Wein LLP. He has experience with clients in almost every industry, including finance, professional services, real estate, automotive, media and manufacturing. Mr. Rapkin works very closely with investment and public firms, seeking to comply with IFRS accounting standards. His roles often require him to work with management on go-public transactions, acquisitions and mergers. His keen attention to detail is an asset to any client he works with, and PlantX is no exception.

Alex Hoffman is the company’s CMO and has spent the last 10 years in the creative field cultivating her passion for design and appreciation for beauty. This is apparent in all of the creative decisions and outcomes seen at PlantX. Her role within the company is to oversee all of the brand marketing activities, establish and execute key processes for rapid growth, and work closely with management to refine the brand’s message for key segments and emerging opportunities. She has a sharp vision for exactly what’s needed to convey the company’s core messages and principles to both the public and investors, and she is a visionary with respect to creative marketing ideas and concepts.

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), closed Friday's trading session at $0.1927, off by 8.2381%, on 138,872 volume with 62 trades. The average volume for the last 3 months is 138,872 and the stock's 52-week low/high is $0.166/$1.85.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading